The MDM2 oncogene is amplified in many human cancers and high expression levels are considered to cause tumour growth. In the general population, there are different polymorphisms in the promoter of this gene and these are thought to influence the levels of MDM2 expression and thereby, potentially cancer risk. We have analysed several MDM2 polymorphisms in large samples of the Norwegian population and found them to influence cancer risk. In particular, we have found one polymorphism (SNP285) to affect binding both Sp1 and estrogen receptor and to reduces the risk of female cancers (breast- and ovarian cancer).
- Knappskog et al. European J. Cancer, 2012
- Gansmo et al. International J. Cancer, 2015
- Helwa et al. Scientific Rep., 2016